Maya Makov-Assif

Maya Makov-Assif

Auto-generated profile, based on publicly available information

Maya Makov-Assif

Clalit Research Institute, Innovation Division, Clalit Health Services, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2024 in NEJM AI
Verified
Journal Article
Closed access
NDNoa Dagan
Noa Dagan
OMOri Magen
Ori Magen
MLMichael Leshchinsky
Michael Leshchinsky
MMMaya Makov-Assif
Maya Makov-Assif
MLMarc Lipsitch
Marc Lipsitch
RBRan D. Balicer
Ran D. Balicer

7 November 2021 in Infectious Diseases
Verified
Journal Article
Closed access
MMMaya Makov-Assif
Maya Makov-Assif
SKSydney Krispin
Sydney Krispin
YBYatir Ben-Shlomo
Yatir Ben-Shlomo
THTal Holander
Tal Holander
NDNoa Dagan
Noa Dagan
NBNoam Barda
Noam Barda
COVID-19 continues to spread throughout the world. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) is used to diagnose COVID-19, with its cycle threshold (Ct) value inversely related to the viral load. The association between Ct values and COVID-19 related outcomes has been studied in the hospital setting but less so in the community. We aimed to estimate the association between Ct values and the severity of community-diagnosed COVID-19 to provide evidence on the utility of Ct testing in this setting. This was a retrospective cohort study based on data from Israel’s largest health organization. The study population included 34,658 individuals who tested positive for COVID-19 by RT-PCR and had available Ct values between June 1st and December 21st, 2020. Outcomes included COVID-19 related symptoms, hospitalization, severe disease, and death. Ct values were modelled both as discrete and continuous exposures. After adjusting for known risk factors for severe COVID-19, low Ct values were associated with symptomatic disease (odds ratio [OR]: 1.51; 95% confidence interval [CI]:1.21–1.84), hospitalization (OR: 1.27; 95%CI: 1.12–1.49), severe disease (OR: 1.80; 95%CI: 1.43–2.27), and death (OR: 1.64; 95%CI: 1.06–2.59). By modelling the exposure as continuous, we noticed a dose-response relationship, with the risk gradually rising with lower Ct values. This study found a significant association between low Ct values and severe COVID-19 related outcomes, with a dose-response relationship. This suggests that Ct values could be helpful in identifying high-risk patients diagnosed in the community.